Search results
Results from the WOW.Com Content Network
Gout is a common form of inflammatory arthritis. It happens due to high levels of uric acid in the body. Researchers estimate that gout impacts one to four percent of people around the world.
The Care Quality Commission (CQC) is an executive non-departmental public body of the Department of Health and Social Care of the United Kingdom.It was established in 2009 to regulate and inspect health and social care providers in England.
In order to achieve foundation trust status, NHS trusts have to pass a variety of tests, which have changed over time. In 2003 only trusts with three stars from the Commission for Health Improvement were eligible for foundation status. In that year Aintree Hospitals, Essex Rivers Healthcare, Newcastle upon Tyne Hospitals and Walsall Hospitals ...
Spire Healthcare alleged in 2013 that a block contract agreed between Blackpool Teaching Hospitals NHS Foundation Trust and the clinical commissioning groups in Blackpool, and Fylde and Wyre offered a "clear incentive" for GPs to refer patients to the foundation trust and that this was anti-competitive behaviour. The contract provided the trust ...
The Mid Staffordshire NHS Foundation Trust Inquiry. [a] Robert Francis: 2010 Vol 1 Vol 2: To give those most affected by poor care at the Mid Staffordshire NHS Foundation Trust an opportunity to tell their stories and to ensure that the lessons to be learned from those experiences 2005 to 2009. Redfern Inquiry Michael Redern 2010 Web
Colchicine is a medication used to prevent and treat gout, [3] [4] to treat familial Mediterranean fever [5] and Behçet's disease, [6] and to reduce the risk of myocardial infarction. [7] The American College of Rheumatology recommends colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids in the treatment of gout.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Pegloticase (trade name Krystexxa) is a medication for the treatment of severe, treatment-refractory, chronic gout. It is a third line treatment in those in whom other treatments are not effective or are not tolerated. [2] The drug is administered by infusion intravenously. Since October 2023, Amgen Inc. has been the marketer of pegloticase in ...